Tags

Type your tag names separated by a space and hit enter

Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.
PLoS One 2009; 4(7):e6294Plos

Abstract

BACKGROUND

The CSF biomarkers tau and Abeta42 can identify patients with AD, even during the preclinical stages. However, previous studies on longitudinal changes of tau and Abeta42 in individual patients with AD and elderly controls report somewhat inconsistent results.

METHODOLOGY/PRINCIPAL FINDINGS

We investigated the levels of tau and Abeta42 at baseline and after 1 year in 100 patients with AD. In a second cohort of 45 AD patients we measured the CSF biomarkers at baseline and after 2 years. Moreover, in 34 healthy elderly controls the CSF biomarkers were followed for 4 years. The baseline levels of tau were increased with >60% in AD patients compared to controls (p<0.001), while baseline Abeta42 levels were decreased with >50% (p<0.001). In the AD group followed for 2 years, tau increased with 16% compared to the baseline levels (p<0.05). However, the levels of tau were stable over 4 years in the controls. The levels of Abeta42 did not change significantly over time in any of the groups. In the patients with AD, tau was moderately associated with worse cognitive performance already at baseline (p<0.05).

CONCLUSIONS/SIGNIFICANCE

Tau and Abeta42 in CSF seem to reflect the underlying disease state in both early and late stages of AD. The slight increase in tau over time observed in the patients with AD is modest when compared to the relatively large difference in absolute tau levels between AD patients and controls. Therefore, these markers maintain their usefulness as state markers over time and might serve as surrogate markers for treatment efficacy in clinical trials.

Authors+Show Affiliations

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19609443

Citation

Buchhave, Peder, et al. "Longitudinal Study of CSF Biomarkers in Patients With Alzheimer's Disease." PloS One, vol. 4, no. 7, 2009, pp. e6294.
Buchhave P, Blennow K, Zetterberg H, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS ONE. 2009;4(7):e6294.
Buchhave, P., Blennow, K., Zetterberg, H., Stomrud, E., Londos, E., Andreasen, N., ... Hansson, O. (2009). Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PloS One, 4(7), pp. e6294. doi:10.1371/journal.pone.0006294.
Buchhave P, et al. Longitudinal Study of CSF Biomarkers in Patients With Alzheimer's Disease. PLoS ONE. 2009 Jul 17;4(7):e6294. PubMed PMID: 19609443.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. AU - Buchhave,Peder, AU - Blennow,Kaj, AU - Zetterberg,Henrik, AU - Stomrud,Erik, AU - Londos,Elisabet, AU - Andreasen,Niels, AU - Minthon,Lennart, AU - Hansson,Oskar, Y1 - 2009/07/17/ PY - 2009/04/15/received PY - 2009/06/16/accepted PY - 2009/7/18/entrez PY - 2009/7/18/pubmed PY - 2009/11/11/medline SP - e6294 EP - e6294 JF - PloS one JO - PLoS ONE VL - 4 IS - 7 N2 - BACKGROUND: The CSF biomarkers tau and Abeta42 can identify patients with AD, even during the preclinical stages. However, previous studies on longitudinal changes of tau and Abeta42 in individual patients with AD and elderly controls report somewhat inconsistent results. METHODOLOGY/PRINCIPAL FINDINGS: We investigated the levels of tau and Abeta42 at baseline and after 1 year in 100 patients with AD. In a second cohort of 45 AD patients we measured the CSF biomarkers at baseline and after 2 years. Moreover, in 34 healthy elderly controls the CSF biomarkers were followed for 4 years. The baseline levels of tau were increased with >60% in AD patients compared to controls (p<0.001), while baseline Abeta42 levels were decreased with >50% (p<0.001). In the AD group followed for 2 years, tau increased with 16% compared to the baseline levels (p<0.05). However, the levels of tau were stable over 4 years in the controls. The levels of Abeta42 did not change significantly over time in any of the groups. In the patients with AD, tau was moderately associated with worse cognitive performance already at baseline (p<0.05). CONCLUSIONS/SIGNIFICANCE: Tau and Abeta42 in CSF seem to reflect the underlying disease state in both early and late stages of AD. The slight increase in tau over time observed in the patients with AD is modest when compared to the relatively large difference in absolute tau levels between AD patients and controls. Therefore, these markers maintain their usefulness as state markers over time and might serve as surrogate markers for treatment efficacy in clinical trials. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/19609443/Longitudinal_study_of_CSF_biomarkers_in_patients_with_Alzheimer's_disease_ L2 - http://dx.plos.org/10.1371/journal.pone.0006294 DB - PRIME DP - Unbound Medicine ER -